Zobrazeno 1 - 10
of 2 975
pro vyhledávání: ''
Autor:
Bhumsuk Keam, Keon Uk Park, Hye Ryun Kim, Keun-Wook Lee, Sung-Bae Kim, Seong Hoon Shin, Jin-Hyuk Choi, Eun Joo Kang, Yun-Gyoo Lee, Hyo Jung Kim, Min Kyoung Kim, Hwan Jung Yun, Kyoung Eun Lee, Jin-Soo Kim, Hee Kyung Ahn
Publikováno v:
Cancer Research and Treatment : Official Journal of Korean Cancer Association
Purpose Certain patient subgroups who do not respond to induction chemotherapy (IC) show inherent chemoresistance in locally advanced head and neck squamous cell carcinoma (LA-HNSCC). This study aimed to assess the prognostic value of IC, and role of
Autor:
Ursa Brown-Glaberman, Hannah M. Linden, Lynn Symonds, Jennifer M. Specht, Eve T. Rodler, Isaac C. Jenkins, Xiaoyu Chai, Georgiana K. Ellis, Pavani Chalasani, Jinny Riedel, Brenda F. Kurland, Julie Gralow, Alison Stopeck, Qian Wu, Vijayakrishna V K Gadi
Publikováno v:
Clin Breast Cancer
INTRODUCTION Neoadjuvant chemotherapy is standard treatment for locally advanced (LABC) or inflammatory breast cancer (IBC). We hypothesized adding sunitinib, a tyrosine kinase inhibitor with anti-tumor and anti-angiogenic activity, to an anthracycli
Autor:
Isamu Okamoto, Tatsuo Ohira, Nobuyuki Yamamoto, Hidehito Horinouchi, Toyoaki Hida, Shinji Atagi, Tatsuro Fukuhara, Miyako Satouchi, Kazuma Kishi, Shunichi Sugawara, Shi Rong Han, Hideo Saka, Victoria Ebiana, Katsuyuki Hotta, Keisuke Aoe, Kazuhiko Nakagawa, Hiroshi Sakai, Hiroaki Okamoto, Kazuo Noguchi, Kaname Nosaki, Atsushi Horiike, Shigeki Umemura, Toshiaki Takahashi, Takayasu Kurata, Nobuyuki Katakami, Akimasa Sekine
Publikováno v:
Cancer Science
Cancer Sci
Cancer Sci
This prespecified subanalysis of the global, randomized controlled phase III KEYNOTE‐024 study of pembrolizumab vs chemotherapy in previously untreated metastatic non‐small‐cell lung cancer without EGFR/ALK alterations and a programmed death li
Autor:
Alexander Stein, Maurice Michel, Jens U. Marquardt, Helge Schroeder, Oliver Waidmann, Marcus-Alexander Woerns, Arndt Weinmann, Markus Moehler, Martin Maenz, Joseph Tintelnot, Friedrich Foerster, Joerg Trojan
Publikováno v:
Future Oncology. 17:3309-3319
Aim: To determine a recommended Phase II dose of the oral fluoropyrimidine trifluridine/tipiracil (FTD/TPI) combined with the multi-kinase inhibitor regorafenib (REG) in refractory metastatic colorectal cancer patients. Materials & methods: A convent
Autor:
Vernon K. Sondak, Andrew Poklepovic, Nikhil I. Khushalani, Jason J. Luke, Sunil Babu, Sigrun Hallmeyer, Zeynep Eroglu, Mario R. Velasco, Emily F. Higgs, Bruce Brockstein, Daniel J Olson, Thomas Krausz, Madhuri Bajaj, Timothy Carll, Riyue Bao, Jose Lutzky, Theodore Karrison, Brian W. Labadie, Thomas F. Gajewski, Yuanyuan Zha
Publikováno v:
J Clin Oncol
PURPOSE Combination of antiprogrammed cell death protein-1 (PD-1) plus anti–cytotoxic T-cell lymphocyte-4 (anti-CTLA-4) immunotherapy shows greater response rates (RRs) than anti-PD-1 antibody alone in melanoma, but RR after initial anti-PD-1 and p
Autor:
Daneng Li, Nicolas Sommer, Wendy Verret, Riad Salem, Riccardo Lencioni, Sairy Hernandez, Beiying Ding
Publikováno v:
Cancer Medicine, Vol 10, Iss 16, Pp 5437-5447 (2021)
Cancer Medicine
Cancer Medicine
Background IMbrave150 is a phase III trial that assessed atezolizumab + bevacizumab (ATEZO/BEV) versus sorafenib (SOR) in patients with unresectable hepatocellular carcinoma (HCC) and demonstrated a significant improvement in clinical outcomes. Explo
Autor:
Veronica Conca, Matteo Clavarezza, Chiara Cremolini, Alessandra Boccaccino, Filippo Pietrantonio, Roberto Moretto, Cristina Granetto, Gianluca Tomasello, Alessandro Bertolini, Antonio Frassoldati, Alfredo Falcone, Mirella Giordano, Alessandro Passardi, Sara Lonardi, Anello Marcello Poma, Gianluca Masi, Gabriella Fontanini, Clara Ugolini, Giuseppe Aprile, Marco Maria Germani
Publikováno v:
European Journal of Cancer. 153:16-26
Background Recent data from the TRIBE2 study have failed to suggest a higher magnitude of benefit from upfront FOLFOXIRI/bevacizumab in patients with BRAF-mutant metastatic colorectal cancer (mCRC) as previously reported in the TRIBE study. Patients
Autor:
Michael C. Kolios, Kashuf Fatima, Daniel DiCenzo, Greg J. Stanisz, Nicole J. Look Hong, Lakshmanan Sannachi, Divya Bhardwaj, Andrea Eisen, William T. Tran, Karina Quiaoit, Robert Dinniwell, Belinda Curpen, Frances C. Wright, Sonal Gandhi, Maureen E. Trudeau, Christine B. Brezden, Mehrdad J. Gangeh, Archya Dasgupta, Wei Yang, Gregory J. Czarnota, Arjun Sahgal, Ali Sadeghi-Naini
Publikováno v:
Cancer Medicine, Vol 9, Iss 16, Pp 5798-5806 (2020)
Cancer Medicine
Cancer Medicine
Background This study was conducted in order to develop a model for predicting response to neoadjuvant chemotherapy (NAC) in patients with locally advanced breast cancer (LABC) using pretreatment quantitative ultrasound (QUS) radiomics. Methods This
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::2018776d702f0a355eb56e7355a5e007
https://doi.org/10.32920/21290982
https://doi.org/10.32920/21290982
Autor:
Lu Xu, Delvys Rodriguez-Abreu, Te Chun Hsia, Mehmet Ali Nahit Sendur, Perran Fulden Yumuk, A. Samkari, Irfan Cicin, Olivier Molinier, Bilal Piperdi, Keynote Investigators, Adrian Langleben, Dae Ho Lee, Balazs Medgyasszay, Francisco Orlandi, Michael Boyer, Ticiana A. Leal, Raffaele Califano, Gregory A. Otterson, Martin Reck, Keunchil Park, Nopadol Soparattanapaisarn
Publikováno v:
Journal of Clinical Oncology. 39:2327-2338
PURPOSE Pembrolizumab monotherapy is standard first-line therapy for metastatic non–small-cell lung cancer (NSCLC) with programmed death ligand 1 (PD-L1) tumor proportion score (TPS) ≥ 50% without actionable driver mutations. It is not known whet
Publikováno v:
Journal of Oncology Pharmacy Practice. 27:1806-1809
Introduction Salivary gland neoplasms (SGNs) respond poorly to the traditional chemotherapy agents limiting the availability of systemic treatment options in the metastatic setting. The recent identification of actionable molecular targets in SGNs ha